Search

Your search keyword '"Taxonera, Carlos"' showing total 543 results
Start Over Author "Taxonera, Carlos"
Sorry, I don't understand your search. ×
543 results on '"Taxonera, Carlos"'

1. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

Author

Márquez-Mosquera, Lucía, Madero, Lucia, Esteve, María, Monfort, David, Varela, Pilare, Vega, Pablo, Martínez, Guillermo Alcaín, Rodriguez-Lago, Iago, García-Bosh, Orlando, Pérez Calle, Jose Lázaro, Merino, Olga, Sierra Ausin, Mónica, Tardillo, Carlos, Lorente Poyatos, Rufo, Fernandez-Salazar, Luis Ignacio, García Sepulcre, Mariana Fe, Bermejo, Fernando, Arce, Nuria Maroto, Bujanda, Luis, Riera, Joan, Ber, Yolanda, Ponferrada Díaz, Ángel, BasCutrina, Francesc, Martinez Montiel, Pilar, Ramos, Laura, Llaó, Jordina, Barreiro- de Acosta, Manuel, Rodriguez Gutierrez, Cristina, Muñoz, Fernando, Sese, Eva, Blat, Rosa, Huguet, Jose M., Marín-Jiménez, Ignacio, Martínez-Flores, Carlos, Van Domselaar, Manuel, Lucendo, Alfredo J., Ginard, Daniel, Menacho, Margarita, Marcos, Noemí Manceñido, Almela, Pedro, de la Piscina, Patricia Ramirez, Argüelles-Arias, Federico, Vilafranca, Carmen Muñoz, Peña, Elena, Alvarez, Pau Gilabert, Santos Fernández, Javier, Coronel, Ana Fuentes, Hernández Villalba, Luis, Andres, Pilar Robledo, Martínez Perez, Teresa, Legido Gil, Jesús, Fernandez, Hipólito, Castillo Regalado, Edgar, Buendía, Lidia, Trapero Martinez, Ana María, Leal, Carles, Miyashiro, Eduardo Iyo, García Herola, Antonio, Frago, Santiago, Novella Duran, María Teresa, Navas López, Victor Manuel, de Prado, Isabel Nicolás, Bebia, Paloma, Botella, Belén, Muñoz, Rosa Ana, Gargallo-Puyuelo, Carla J., Ricart, Elena, Iglesias, Eva, de Francisco, Ruth, Gisbert, Javier P., Taxonera, Carlos, Mañosa, Miriam, Aguas Peris, Mariam, Navarrete-Muñoz, Eva María, Sanahuja, Ana, Guardiola, Jordi, Mesonero, Francisco, Rivero Tirado, Montserrat, Barrio, Jesús, Vera Mendoza, Isabel, de Castro Parga, Luisa, García-Planella, Esther, Calvet, Xavier, Martín Arranz, María Dolores, García, Santiago, Sicilia, Beatriz, Carpio, Daniel, Domenech, Eugeni, and Gomollón, Fernando

Published
2024
Full Text
View/download PDF

2. SEX-RELATED DIFFERENCES IN THE PHENOTYPE AND COURSE OF INFLAMMATORY BOWEL DISEASE: SEXEII STUDY OF ENEIDA.

Author

Gargallo-Puyuelo, Carla J., primary, Ricart, Elena, additional, Iglesias, Eva, additional, de Francisco, Ruth, additional, Gisbert, Javier P., additional, Taxonera, Carlos, additional, Mañosa, Miriam, additional, Peris, Mariam Aguas, additional, Navarrete-Muñoz, Eva María, additional, Sanahuja, Ana, additional, Guardiola, Jordi, additional, Mesonero, Francisco, additional, Tirado, Montserrat Rivero, additional, Barrio, Jesús, additional, Mendoza, Isabel Vera, additional, de Castro Parga, Luisa, additional, García-Planella, Esther, additional, Calvet =, Xavier, additional, Martín Arranz, María Dolores, additional, García, Santiago, additional, Sicilia, Beatriz, additional, Carpio, Daniel, additional, Domenech, Eugeni, additional, Gomollón, Fernando, additional, Márquez-Mosquera, Lucía, additional, Madero, Lucia, additional, Esteve, María, additional, Monfort, David, additional, Varela, Pilare, additional, Vega, Pablo, additional, Martínez, Guillermo Alcaín, additional, Rodriguez-Lago, Iago, additional, García-Bosh, Orlando, additional, Pérez Calle, Jose Lázaro, additional, Merino, Olga, additional, Ausin, Mónica Sierra, additional, Tardillo, Carlos, additional, Poyatos, Rufo Lorente, additional, Fernandez-Salazar, Luis Ignacio, additional, García Sepulcre, Mariana Fe, additional, Bermejo, Fernando, additional, Arce, Nuria Maroto, additional, Bujanda, Luis, additional, Riera, Joan, additional, Ber, Yolanda, additional, Díaz, Ángel Ponferrada, additional, Cutrina, Francesc Bas-, additional, Montiel, Pilar Martinez, additional, Ramos, Laura, additional, Llaó, Jordina, additional, Barreiro- de Acosta, Manuel, additional, Gutierrez, Cristina Rodriguez, additional, Muñoz, Fernando, additional, Sese, Eva, additional, Blat, Rosa, additional, Huguet, Jose M., additional, Marín-Jiménez, Ignacio, additional, Martínez-Flores, Carlos, additional, Van Domselaar, Manuel, additional, Lucendo, Alfredo J., additional, Ginard, Daniel, additional, Menacho, Margarita, additional, Marcos, Noemí Manceñido, additional, Almela, Pedro, additional, Ramirez de la Piscina, Patricia, additional, Argüelles-Arias, Federico, additional, Vilafranca, Carmen Muñoz, additional, Peña, Elena, additional, Alvarez, Pau Gilabert, additional, Fernández, Javier Santos, additional, Coronel, Ana Fuentes, additional, Villalba, Luis Hernández, additional, Andres, Pilar Robledo, additional, Perez, Teresa Martínez, additional, Gil, Jesús Legido, additional, Fernandez, Hipólito, additional, Regalado, Edgar Castillo, additional, Buendía, Lidia, additional, Trapero Martinez, Ana María, additional, Leal, Carles, additional, Miyashiro, Eduardo Iyo, additional, Herola, Antonio García, additional, Frago, Santiago, additional, Novella Duran, María Teresa, additional, Navas López, Victor Manuel, additional, de Prado, Isabel Nicolás, additional, Bebia, Paloma, additional, Botella, Belén, additional, and Muñoz, Rosa Ana, additional

Published
2024
Full Text
View/download PDF

3. Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved

Author

Guijarro, Luis G., Cano-Martínez, David, Toledo-Lobo, M.Val, Salinas, Patricia Sanmartín, Chaparro, María, Gómez-Lahoz, Ana M., Zoullas, Sofía, Rodríguez-Torres, Rosa, Román, Irene D., Monasor, Laura Sebastián, Ruiz-Llorente, Lidia, del Carmen Boyano-Adánez, María, Guerra, Iván, Iborra, Marisa, Cabriada, José Luis, Bujanda, Luis, Taxonera, Carlos, García-Sánchez, Valle, Marín-Jiménez, Ignacio, Acosta, Manuel Barreiro-de, Vera, Isabel, Martín-Arranz, María Dolores, Mesonero, Francisco, Sempere, Laura, Gomollón, Fernando, Hinojosa, Joaquín, Alvarez-Mon, Melchor, Gisbert, Javier P., Ortega, Miguel A., Hernández-Breijo, Borja, and on behalf of the PREDICROHN study group from GETECCU

Published
2021
Full Text
View/download PDF

4. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

Author

Calafat, Margalida, primary, Torres, Paola, additional, Tosca-Cuquerella, Joan, additional, Sánchez-Aldehuelo, Rubén, additional, Rivero, Montserrat, additional, Iborra, Marisa, additional, González-Vivo, María, additional, Vera, Isabel, additional, de Castro, Luisa, additional, Bujanda, Luis, additional, Barreiro-de Acosta, Manuel, additional, González-Muñoza, Carlos, additional, Calvet, Xavier, additional, Benítez, José Manuel, additional, Llorente-Barrio, Mónica, additional, Surís, Gerard, additional, Cañete, Fiorella, additional, Arias-García, Lara, additional, Monfort, David, additional, Castaño-García, Andrés, additional, Garcia-Alonso, Francisco Javier, additional, Huguet, José M., additional, Marín-Jímenez, Ignacio, additional, Lorente, Rufo, additional, Martín-Cardona, Albert, additional, Ferrer, Juan Ángel, additional, Camo, Patricia, additional, Gisbert, Javier P., additional, Pajares, Ramón, additional, Gomollón, Fernando, additional, Castro-Poceiro, Jesús, additional, Morales-Alvarado, Jair, additional, Llaó, Jordina, additional, Rodríguez, Andrés, additional, Rodríguez, Cristina, additional, Pérez-Galindo, Pablo, additional, Navarro, Mercè, additional, Jiménez-García, Nuria, additional, Carrillo-Palau, Marta, additional, Blázquez-Gómez, Isabel, additional, Sesé, Eva, additional, Almela, Pedro, additional, Ramírez de la Piscina, Patricia, additional, Taxonera, Carlos, additional, Rodríguez-Lago, Iago, additional, Cabrinety, Lidia, additional, Vela, Milagros, additional, Mínguez, Miguel, additional, Mesonero, Francisco, additional, García, María José, additional, Aguas, Mariam, additional, Márquez, Lucía, additional, Silva Porto, Marisol, additional, Pineda, Juan R., additional, García-Etxebarría, Koldo, additional, Bertoletti, Federico, additional, Brunet, Eduard, additional, Mañosa, Míriam, additional, and Domènech, Eugeni, additional

Published
2024
Full Text
View/download PDF

7. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn’s Disease: A National, Multicentre Study Based on ENEIDA Registry

Author

Casas Deza, Diego, primary, Polo Cuadro, Cristina, additional, de Francisco, Ruth, additional, Vela González, Milagros, additional, Bermejo, Fernando, additional, Blanco, Ignacio, additional, de la Serna, Álvaro, additional, Bujanda, Luis, additional, Bernal, Lorena, additional, Rueda García, José Luis, additional, Gargallo-Puyuelo, Carla J, additional, Fuentes-Valenzuela, Esteban, additional, Castro, Beatriz, additional, Guardiola, Jordi, additional, Ladrón, Gemma, additional, Suria, Carles, additional, Sáez Fuster, Julia, additional, Gisbert, Javier P, additional, Sicilia, Beatriz, additional, Gomez, Raquel, additional, Muñoz Vilafranca, Carmen, additional, Barreiro-De Acosta, Manuel, additional, Peña, Elena, additional, Castillo Pradillo, Marta, additional, Cerrillo, Elena, additional, Calvet, Xavier, additional, Manceñido, Noemí, additional, Monfort i Miquel, David, additional, Marín, Sandra, additional, Roig, Cristina, additional, Marce, Ainhoa, additional, Ramírez de Piscina, Patricia, additional, Betoré, Elena, additional, Martin-Cardona, Albert, additional, Teller, Marta, additional, Alonso Abreu, Inmaculada, additional, Maroto, Nuria, additional, Frago, Santiago, additional, Gardeazabal, Diego, additional, Pérez-Martínez, Isabel, additional, Febles González, Ángel David, additional, Barrero, Sara, additional, Taxonera, Carlos, additional, García de la Filia, Irene, additional, Ezkurra-Altuna, Ander, additional, Madero, Lucía, additional, Martín-Arranz, María Dolores, additional, Gomollón, Fernando, additional, Domènech, Eugeni, additional, and García-López, Santiago, additional

Published
2023
Full Text
View/download PDF

10. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn’s patients: Results of the APPRECIA trial

Author

Taxonera, Carlos, López-Sanromán, Antonio, Vera-Mendoza, Isabel, Domènech, Eugeni, Ruiz, Vicente Vega, Marín-Jiménez, Ignacio, Guardiola, Jordi, Castro, Luisa, Esteve, María, Iglesias, Eva, Ceballos, Daniel, Martínez-Montiel, Pilar, Gisbert, Javier P., Mínguez, Miguel, Echarri, Ana, Calvet, Xavier, Barrio, Jesús, Hinojosa, Joaquín, Martín-Arranz, María Dolores, Márquez-Mosquera, Lucía, Bermejo, Fernando, Rimola, Jordi, Alba, Cristina, Pons, Vicente, and Nos, Pilar

Published
2019
Full Text
View/download PDF

11. Determinación de la contribución de valor de filgotinib para el tratamiento de la colitis ulcerosa de moderada a grave mediante el análisis de decisión multicriterio (MCDA)

Author

Taxonera, Carlos, primary, Sala, Ferran, additional, Martín, Isabel, additional, Nazco, Júlia, additional, Marín, Laura, additional, Nos, Pilar, additional, Amián, Raúl, additional, Arocas, Vicente, additional, Martín, Arancha, additional, Blasco, Martí, additional, and Subirán, Rafael, additional

Published
2023
Full Text
View/download PDF

13. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

Author

Chaparro, María, Barreiro-de Acosta, Manuel, Echarri, Ana, Almendros, Rosendo, Barrio, Jesús, Llao, Jordina, Gomollón, Fernando, Vera, Maribel, Cabriada, José Luis, Guardiola, Jordi, Guerra, Iván, Beltrán, Belén, Roncero, Oscar, Busquets, David, Taxonera, Carlos, Calvet, Xavier, Ferreiro-Iglesias, Rocío, Ollero Pena, Virginia, Bernardo, David, Donday, María G., Garre, Ana, Godino, Ana, Díaz, Ana, and Gisbert, Javier P.

Published
2019
Full Text
View/download PDF

14. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

Author

Iborra, Marisa, García-Morales, Natalia, Rubio, Saoia, Bertoletti, Federico, Calvo, Marta, Taxonera, Carlos, Boscá-Watts, Marta Maia, Sierra, Mónica, Mancenido, Noemí, Beltrán, Belén, Nantes Castillejo, Óscar, García-Planella, Esther, Vera, Isabel, Alba, Cristina, Martí-Aguado, David, Ballester, María Pilar, Cano-Sanz, Noelia, Pajares-Villarroya, Ramón, Cerrillo, Elena, Cañada, Antonio, and Nos, Pilar

Published
2020
Full Text
View/download PDF

15. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohnʼs Disease: A Nationwide Study With Propensity-Matched Score Analysis

Author

Cañete, Fiorella, Mañosa, Míriam, Pérez-Martínez, Isabel, Barreiro-de Acosta, Manuel, González-Sueyro, Ramiro C., Nos, Pilar, Iglesias-Flores, Eva, Gutiérrez, Ana, Bujanda, Luis, Gordillo, Jordi, Ríos León, Raquel, Casanova, María José, Villoria, Albert, Rodríguez-Lago, Iago, López Serrano, Pilar, García-Herola, Antonio, Ramírez-de la Piscina, Patricia, Navarro-Llavat, Mercè, Taxonera, Carlos, Barrio, Jesús, Ramos, Laura, Navarro, Pablo, Benítez-Leiva, Olga, Calafat, Margalida, and Domènech, Eugeni

Published
2020
Full Text
View/download PDF

16. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease

Author

Chaparro, María, Guerra, Iván, Iborra, Marisa, Cabriada, José Luis, Bujanda, Luis, Taxonera, Carlos, García-Sánchez, Valle, Marín-Jiménez, Ignacio, Barreiro-de Acosta, Manuel, Vera, Isabel, Martín-Arranz, María Dolores, Hernández-Breijo, Borja, Mesonero, Francisco, Sempere, Laura, Gomollón, Fernando, Hinojosa, Joaquín, Bermejo, Fernando, Beltrán, Belén, Rodríguez Pescador, Ainhoa, Banales, Jesús María, Olivares, David, Aguilar-Melero, Patricia, Menchén, Luis, Ferreiro-Iglesias, Rocío, Blazquez Gomez, Isabel, Benítez García, Belén, Guijarro, Luis González, Marin, Alicia, Bernardo, David, and Gisbert, Javier P.

Published
2020
Full Text
View/download PDF

17. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Author

Casanova, María José, Chaparro, María, Mínguez, Miguel, Ricart, Elena, Taxonera, Carlos, García-López, Santiago, Guardiola, Jordi, López-San Román, Antonio, Iglesias, Eva, Beltrán, Belén, Sicilia, Beatriz, Vera, María Isabel, Hinojosa, Joaquín, Riestra, Sabino, Domènech, Eugeni, Calvet, Xavier, Pérez-Calle, José Lázaro, Martín-Arranz, María Dolores, Aldeguer, Xavier, Rivero, Montserrat, Monfort, David, Barrio, Jesús, Esteve, María, Márquez, Lucía, Lorente, Rufo, García-Planella, Esther, de Castro, Luisa, Bermejo, Fernando, Merino, Olga, Rodríguez-Pérez, Antonio, Martínez-Montiel, Pilar, Van Domselaar, Manuel, Alcaín, Guillermo, Domínguez-Cajal, Manuel, Muñoz, Carmen, Gomollón, Fernando, Fernández-Salazar, Luis, García-Sepulcre, Mariana Fe, Rodríguez-Lago, Iago, Gutiérrez, Ana, Argüelles-Arias, Federico, Rodriguez, Cristina, Rodríguez, Gloria Esther, Bujanda, Luis, Llaó, Jordina, Varela, Pilar, Ramos, Laura, Huguet, José María, Almela, Pedro, Romero, Patricia, Navarro-Llavat, Mercè, Abad, Águeda, Ramírez-de la Piscina, Patricia, Lucendo, Alfredo J, Sesé, Eva, Madrigal, Rosa Eva, Charro, Mara, García-Herola, Antonio, Pajares, Ramón, Khorrami, Sam, and Gisbert, Javier P

Published
2020
Full Text
View/download PDF

18. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry

Author

Cañete, Fiorella, Mañosa, Míriam, Casanova, María José, González-Sueyro, Ramiro C, Barrio, Jesús, Bermejo, Fernando, Nos, Pilar, Iglesias-Flores, Eva, García-Planella, Esther, Pérez-Calle, José Lázaro, Vicente, Raquel, Vera, Maribel, Ramos, Laura, Rivero, Montserrat, De Francisco, Ruth, Montserrat, Antonia, Benítez, Olga, Navarro, Pablo, Taxonera, Carlos, Hinojosa, Esther, Márquez-Mosquera, Lucía, Navarro-Llavat, Mercé, Ramírez-de la Piscina, Patricia, Gomollón, Fernando, Rodríguez-Alonso, Lorena, Núñez-Alonso, Alejandro, Fernández-Salazar, Luis, Almela, Pedro, Ríos León, Raquel, De Castro, Luisa, Gisbert, Javier P, Ricart, Elena, Cabré, Eduard, and Domènech, Eugeni

Published
2019
Full Text
View/download PDF

23. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent

Author

R-Grau, María del Carmen, Chaparro, María, Mesonero, Francisco, Barreiro-de Acosta, Manuel, Castro, Luisa, Castro, Manuel, Domènech, Eugeni, Mancenido, Noemí, Pérez-Calle, José Lázaro, Taxonera, Carlos, Barrio, Jesús, De Francisco, Ruth, Fernández-Salgado, Estela, Luzón, Lara, Merino, Olga, Oltra, Lorena, Saro, Cristina, Bermejo, Fernando, García-Sánchez, Valle, Ginard, Daniel, Gutiérrez, Ana, Vera, Isabel, Antón, Rosario, Ber, Yolanda, Calvet, Xavier, and Gisbert, Javier P.

Published
2016
Full Text
View/download PDF

24. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

Author

Taxonera, Carlos, Iglesias, Eva, Muñoz, Fernando, Calvo, Marta, Barreiro-de Acosta, Manuel, Busquets, David, Calvet, Xavier, Rodríguez, Antonio, Pajares, Ramón, Gisbert, Javier P., López-Serrano, Pilar, Pérez-Calle, José Luís, Ponferrada, Ángel, De la Coba, Cristóbal, Bermejo, Fernando, Chaparro, María, Olivares, David, Alba, Cristina, and Fernández-Blanco, Ignacio

Published
2017
Full Text
View/download PDF

26. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

Author

Chaparro, María, primary, Baston-Rey, Iria, additional, Fernández Salgado, Estela, additional, González García, Javier, additional, Ramos, Laura, additional, Diz-Lois Palomares, María Teresa, additional, Argüelles-Arias, Federico, additional, Iglesias Flores, Eva, additional, Cabello, Mercedes, additional, Rubio Iturria, Saioa, additional, Núñez Ortiz, Andrea, additional, Charro, Mara, additional, Ginard, Daniel, additional, Dueñas Sadornil, Carmen, additional, Merino Ochoa, Olga, additional, Busquets, David, additional, Iyo, Eduardo, additional, Gutiérrez Casbas, Ana, additional, Ramírez de la Piscina, Patricia, additional, Boscá-Watts, Marta Maia, additional, Arroyo, Maite, additional, García, María José, additional, Hinojosa, Esther, additional, Gordillo, Jordi, additional, Martínez Montiel, Pilar, additional, Velayos Jiménez, Benito, additional, Quílez Ivorra, Cristina, additional, Vázquez Morón, Juan María, additional, Huguet, José María, additional, González-Lama, Yago, additional, Muñagorri Santos, Ana Isabel, additional, Amo, Víctor Manuel, additional, Martín Arranz, María Dolores, additional, Bermejo, Fernando, additional, Martínez Cadilla, Jesús, additional, Rubín de Célix, Cristina, additional, Fradejas Salazar, Paola, additional, López San Román, Antonio, additional, Jiménez, Nuria, additional, García-López, Santiago, additional, Figuerola, Anna, additional, Jiménez, Itxaso, additional, Martínez Cerezo, Francisco José, additional, Taxonera, Carlos, additional, Varela, Pilar, additional, de Francisco, Ruth, additional, Monfort, David, additional, Molina Arriero, Gema, additional, Hernández-Camba, Alejandro, additional, García Alonso, Francisco Javier, additional, Van Domselaar, Manuel, additional, Pajares-Villarroya, Ramón, additional, Núñez, Alejandro, additional, Rodríguez Moranta, Francisco, additional, Marín-Jiménez, Ignacio, additional, Robles Alonso, Virginia, additional, Martín Rodríguez, María del Mar, additional, Camo-Monterde, Patricia, additional, García Tercero, Iván, additional, Navarro-Llavat, Mercedes, additional, García, Lara Arias, additional, Hervías Cruz, Daniel, additional, Kloss, Sebastian, additional, Passey, Alun, additional, Novella, Cynthia, additional, Vispo, Eugenia, additional, Barreiro-de Acosta, Manuel, additional, and Gisbert, Javier P., additional

Published
2022
Full Text
View/download PDF

28. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

Author

Taxonera, Carlos, Barreiro-de Acosta, Manuel, Calvo, Marta, Saro, Cristina, Bastida, Guillermo, Martín-Arranz, María D., Gisbert, Javier P., García-Sánchez, Valle, Marín-Jiménez, Ignacio, Bermejo, Fernando, Chaparro, María, Ponferrada, Ángel, Martínez-Montiel, María P., Pajares, Ramón, de Gracia, Celia, Olivares, David, Alba, Cristina, Mendoza, Juan L., and Fernández-Blanco, Ignacio

Published
2015
Full Text
View/download PDF

29. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

Author

Taxonera, Carlos, primary, Fernández‐Aceñero, María Jesús, additional, Olivares, David, additional, Calvo, Marta, additional, Casis, Begoña, additional, Bermejo, Fernando, additional, López Serrano, Pilar, additional, Iborra, Marisa, additional, Mesonero, Francisco, additional, Boscá Watts, Maia, additional, Díaz del Arco, Cristina, additional, Vera, Isabel, additional, Olivares, Sonsoles, additional, Algaba, Alicia, additional, and Alba, Cristina, additional

Published
2022
Full Text
View/download PDF

30. Mo1534: ASSOCIATION OF GOLIMUMAB TROUGH CONCENTRATIONS DURING MAINTENANCE WITH ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS.

Author

Taxonera, Carlos, primary, Fernández-Aceñero, María Jesús, additional, Olivares, David, additional, Calvo, Marta, additional, Casis, Begoña, additional, Bermejo, Fernando, additional, López, Pilar, additional, Iborra, Marisa, additional, Mesonero, Francisco, additional, Bosca-Watts, Marta Maria, additional, Arco, Cristina Díaz del, additional, Vera, Isabel, additional, Olivares, Sonsoles, additional, and Alba, Cristina, additional

Published
2022
Full Text
View/download PDF

33. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

Author

Chaparro, María, Baston-Rey, Iria, Fernández-Salgado, Estela, González García, Javier, Ramos López, Laura, Diz-Lois Palomares, María Teresa, Argüelles-Arias, Federico, Iglesias Flores, Eva, Cabello, Mercedes, Rubio Iturria, Saioa, Núñez Ortiz, Andrea, Charro, Mara, Ginard, Daniel, Dueñas Sadornil, Carmen, Merino Ochoa, Olga, Busquets, David, Iyo, Eduardo, Gutiérrez Casbas, Ana, Ramírez de la Piscina, Patricia, Bosca-Watts, Maia, Arroyo, Maite, Garcia, Maria José, Hinojosa, Esther, Gordillo, Jordi, Martínez Montiel, Pilar, Velayos Jiménez, Benito, Quílez Ivorra, Cristina, Vázquez Morón, Juan María, María Huguet, José, González-Lama, Yago, Muñagorri Santos, Ana Isabel, Amo, Víctor Manuel, Martín-Arranz, María Dolores, Bermejo, Fernando, Martínez Cadilla, Jesús, Rubín de Célix, Cristina, Fradejas Salazar, Paola, San Román, Antonio López, Jiménez, Nuria, García López, Santiago, Figuerola, Anna, Jiménez, Itxaso, Martínez Cerezo, Francisco José, Taxonera, Carlos, Varela, Pilar, de Francisco, Ruth, Monfort, David, Molina Arriero, Gema, Hernández Camba, Alejandro, P. Gisbert, Javier, Van Domselaar, Manuel, Pajares Villarroya, Ramón, Núñez, Alejandro, Rodríguez Moranta, Francisco, Marín-Jiménez, Ignacio, Robles Alonso, Virginia, Martín Rodríguez, María del Mar, Camo-Monterde, Patricia, García Tercero, Iván, Navarro Llavat, Mercedes, Arias García, Lara, Hervías Cruz, Daniel, Sulleiro, Sara, Novella, Cynthia, Vispo, Eugenia, Barreiro de-Acosta, Manuel, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Chaparro M] Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain. [Baston-Rey I] Gastroenterology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain. [Fernández-Salgado E] Gastroenterology Department, Complejo Hospitalario de Pontevedra, Pontevedra, Spain. [González García J] Gastroenterology Department, Hospital Público Comarcal la Inmaculada, Almería, Spain. [Ramos L] Gastroenterology Department, Hospital Universitario de Canarias, Tenerife, Spain. [Diz-Lois Palomares MT] Gastroenterology Department, Hospital Universitario A Coruña, A Coruña, Spain. [Robles Alonso V] Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Crohn’s disease, safety, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], effectiveness, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [CHEMICALS AND DRUGS], ustekinumab, Crohn Disease, Humans, Immunology and Allergy, aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::/therapeutic use [Other subheadings], real-world evidence, Retrospective Studies, Anticossos monoclonals - Ús terapèutic, Otros calificadores::/uso terapéutico [Otros calificadores], Remission Induction, Gastroenterology, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES], Crohn, Malaltia de - Tractament, Crohn's disease, Treatment Outcome, Avaluació de resultats (Assistència sanitària), Ustekinumab, Immunosuppressive Agents
Abstract

Crohn’s disease; Effectiveness; Ustekinumab Enfermedad de Crohn; Eficacia; Ustekinumab Malaltia de Crohn; Efectivitat; Ustekinumab Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice. This work was supported by Janssen-Cilag Spain. This sponsor had a partial role in study design, analysis, and interpretation of data. Medical writing and editorial assistance for the preparation of this article was funded by Janssen-Cilag Spain. This assistance was provided by the following individuals, who are either employees of Springer Healthcare Communications (S.H.C.), or were contracted by S.H.C. to undertake editorial work in connection with the preparation of the article: Eliana Mesa, MD, Sheridan Henness, PhD, Fernando Sánchez Barbero, PhD.

Published
2022

34. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

Author

Riestra, Sabino, Taxonera, Carlos, Zabana, Yamile, Carpio, Daniel, Chaparro, María, Barrio, Jesús, Rivero, Montserrat, López Sanroman, Antonio, Esteve, María, Francisco, Ruth de, Bastida, Guillermo, García López, Santiago, Mañosa, Miriam, Martin Arranz, María Dolores, Pérez Calle, José Lázaro, Guardiola, Jordi, Muñoz, Fernando, Arranz, Laura, Cabriada, José Luis, García Sepulcre, Mariana Fe, Navarro, Mercè, Montoro Huguet, Miguel Ángel, Ricart, Elena, Bermejo, Fernando, Calvet, Xavier, Piqueras, Marta, Garcia Planella, Esther, Márquez, Lucía, Mínguez, Miguel, Van Domselar, Manuel, Bujanda, Luis, Aldeguer, Xavier, Sicilia, Beatriz, Iglesias, Eva, Alcaín, Guillermo, Pérez Martínez, Isabel, Rolle, Valeria, Castaño García, Andrés, Gisbert, Javier P., Domènech, Eugeni, The ENEIDA Registry From GETECCU, [Riestra S] Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. [Taxonera C] Gastroenterology Department, Hospital Clínico Universitario San Carlos, Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Zabana Y] Gastroenterology Department, Hospital Universitari Mútua Terrassa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Terrassa, Spain. [Carpio D] Gastroenterology Department, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain. [Chaparro M] Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. [Barrio J] Gastroenterology Department, Hospital Universitario Río Hortega, Valladolid, Spain. [Piqueras M] Servei de Gastroenterologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain, and Consorci Sanitari de Terrassa

Subjects
Tuberculin skin test, Tuberculosi, infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Actinomycetales::micobacteriosis::tuberculosis::tuberculosis latente [ENFERMEDADES], latent tuberculosis infection, Interferó, tuberculin skin test, General Medicine, Interferon gamma release assays, Inflammatory bowel diseases, interferon gamma release assays, Inflammatory bowel disease, diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::pruebas inmunológicas::análisis de la liberación del interferón gamma [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Malalties inflamatòries intestinals, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal [ENFERMEDADES], inflammatory bowel disease, Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Immunologic Tests::Interferon-gamma Release Tests [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Tuberculosis, Latent tuberculosis infection, Intestins - Inflamació, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases [DISEASES], Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis::Latent Tuberculosis [DISEASES]
Abstract

Inflammatory bowel disease; Interferon gamma release assays; Latent tuberculosis infection Enfermedad inflamatoria intestinal; Ensayos de liberación de interferón gamma; Infección tuberculosa latente Malaltia inflamatòria intestinal; Assajos d'alliberament gamma d'interferó; Infecció tuberculosa latent Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-ץ-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18−20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50−0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66−0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20−22%] vs. 14% [95% CI 13−16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM.

Published
2022

35. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

Author

Guerra, Iván, Algaba, Alicia, Pérez-Calle, José Lázaro, Chaparro, María, Marín-Jiménez, Ignacio, García-Castellanos, Raquel, González-Lama, Yago, López-Sanromán, Antonio, Manceñido, Noemí, Martínez-Montiel, Pilar, Quintanilla, Elvira, Taxonera, Carlos, Villafruela, Mónica, Romero-Maté, Alberto, López-Serrano, Pilar, Gisbert, Javier P., and Bermejo, Fernando

Published
2012
Full Text
View/download PDF

37. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

Author

Guijarro, Luis G., primary, Cano-Martínez, David, additional, Toledo-Lobo, M. Val, additional, Ruiz-Llorente, Lidia, additional, Chaparro, María, additional, Guerra, Iván, additional, Iborra, Marisa, additional, Cabriada, José Luis, additional, Bujanda, Luis, additional, Taxonera, Carlos, additional, García-Sánchez, Valle, additional, Marín-Jiménez, Ignacio, additional, Barreiro-de Acosta, Manuel, additional, Vera, Isabel, additional, Martín-Arranz, María Dolores, additional, Mesonero, Francisco, additional, Sempere, Laura, additional, Gomollón, Fernando, additional, Hinojosa, Joaquín, additional, Zoullas, Sofía, additional, Monserrat, Jorge, additional, Menor-Salvan, Cesar, additional, Alvarez-Mon, Melchor, additional, Gisbert, Javier P., additional, Ortega, Miguel A., additional, and Hernández-Breijo, Borja, additional

Published
2022
Full Text
View/download PDF

40. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

Author

Eliadou, Elena, Moleiro, Joana, Ribaldone, Davide Giuseppe, Astegiano, Marco, Rothfuss, Katja, Taxonera, Carlos, Ghalim, Fahd, Carbonnel, Franck, Verstockt, Bram, Festa, Stefano, Maia, Luís, Berrozpe, Ana, Zagorowicz, Edyta, Savarino, Edoardo, Ellul, Pierre, Vavricka, Stephan R, Calvo, Marta, Koutroubakis, Ioannis, Hoentjen, Frank, Luis, Fernández Salazar, Callela, Francesca, Cañete Pizarro, Fiorella, Soufleris, Konstantinos, Sonnenberg, Elena, Cavicchi, Maryan, Wypych, Joanna, Hommel, Christophe, Ghiani, Alessandro, Fiorino, Gionata, ECCO CONFER COMMITTEE, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service de gastro-entérologie

Subjects
Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, medicine.medical_treatment, Anti-Inflammatory Agents, Comorbidity, Disease, Global Health, Inflammatory bowel disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Lung transplantation, 030212 general & internal medicine, Glucocorticoids, Lung, business.industry, General Medicine, Middle Aged, respiratory system, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, respiratory tract diseases, Hospitalization, Pneumonia, Outcome and Process Assessment, Health Care, medicine.anatomical_structure, Etiology, Female, 030211 gastroenterology & hepatology, Symptom Assessment, Lung Diseases, Interstitial, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Lung Transplantation
Abstract

Background Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear. Methods This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician. Results We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn’s disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients. Conclusions ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases.

Published
2020

43. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII).

Author

Zabana, Yamile, Marín-Jiménez, Ignacio, Rodríguez-Lago, Iago, Vera, Isabel, Martín-Arranz, María Dolores, Guerra, Iván, P. Gisbert, Javier, Mesonero, Francisco, Benítez, Olga, Taxonera, Carlos, Ponferrada-Díaz, Ángel, Piqueras, Marta, J. Lucendo, Alfredo, Caballol, Berta, Mañosa, Míriam, Martínez-Montiel, Pilar, Bosca-Watts, Maia, Gordillo, Jordi, Bujanda, Luis, and Manceñido, Noemí

Subjects
INFLAMMATORY bowel diseases, COVID-19, CASE-control method, OCCUPATIONAL exposure
Abstract

(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case–control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March–July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3–5.9), occupational risk (OR: 2.9; 95%CI: 1.8–4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2–2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09–0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. A phase II study of laquinimod in Crohnʼs disease

Author

DʼHaens, Geert, Sandborn, William J, Colombel, Jean Frederic, Rutgeerts, Paul, Brown, Kurt, Barkay, Hadas, Sakov, Anat, Haviv, Asi, Feagan, Brian G, Baert, Filip, Dupas, Jean-Louis, Bouhnik, Yoram, Bonaz, Bruno, Hebuterne, Xavier, Allez, Matthieu, Israeli, Eran, Fraser, Gerald, Segol, Ori, Fishman, Sigal, Lahat, Adi, Melzer, Ehud, Pallone, Francesco, Campieri, Massimo, Gasbarrini, Antonio, Kohn, Anna, Vecchi, Maurizo, Ponsioen, Cyriel, Van der Woude, Janneke, Rydzewska, Grazyna, Mach, Tomasz, Paradowski, Leszek, Wright, John Philip, Watermeyer, Gillian Ann, Pettengell, Keith Edward, Mahomed, Adam Dawood, Prins, Maarten Jeroen, Aboo, Nazimuddin, Diaz, Julian Panes, Taxonera, Carlos, Gisbert, Javier, Hinojosa, Joaquin, Garcia, Fernand Gomollon, Sanchez, Valle Garcia, Parkes, Miles, Probert, Chris, Leiper, Keith, Nwokolo, Chuka, Mayberry, John, and Bloom, Stuart

Published
2015
Full Text
View/download PDF

46. sj-docx-4-tag-10.1177_17562848211056157 ��� Supplemental material for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Author

Taxonera, Carlos, Mart��nez-Montiel, Mar��a Pilar, Barreiro-de-Acosta, Manuel, Vera, Isabel, Lorente, Rufo, Vega, Pablo, Diz-Lois, Mar��a Teresa, Fuentes Coronel, Ana Mar��a, P��rez Calle, Jos�� L��zaro, Casis, Bego��a, Ferreiro-Iglesias, Roc��o, Calvo, Marta, Olivares, David, and Alba, Cristina

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-4-tag-10.1177_17562848211056157 for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study by Carlos Taxonera, Mar��a Pilar Mart��nez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, Mar��a Teresa Diz-Lois, Ana Mar��a Fuentes Coronel, Jos�� L��zaro P��rez Calle, Bego��a Casis, Roc��o Ferreiro-Iglesias, Marta Calvo, David Olivares and Cristina Alba in Therapeutic Advances in Gastroenterology

Published
2021
Full Text
View/download PDF

47. sj-docx-3-tag-10.1177_17562848211056157 ��� Supplemental material for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Author

Taxonera, Carlos, Mart��nez-Montiel, Mar��a Pilar, Barreiro-de-Acosta, Manuel, Vera, Isabel, Lorente, Rufo, Vega, Pablo, Diz-Lois, Mar��a Teresa, Fuentes Coronel, Ana Mar��a, P��rez Calle, Jos�� L��zaro, Casis, Bego��a, Ferreiro-Iglesias, Roc��o, Calvo, Marta, Olivares, David, and Alba, Cristina

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tag-10.1177_17562848211056157 for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study by Carlos Taxonera, Mar��a Pilar Mart��nez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, Mar��a Teresa Diz-Lois, Ana Mar��a Fuentes Coronel, Jos�� L��zaro P��rez Calle, Bego��a Casis, Roc��o Ferreiro-Iglesias, Marta Calvo, David Olivares and Cristina Alba in Therapeutic Advances in Gastroenterology

Published
2021
Full Text
View/download PDF

48. sj-docx-1-tag-10.1177_17562848211056157 ��� Supplemental material for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Author

Taxonera, Carlos, Mart��nez-Montiel, Mar��a Pilar, Barreiro-de-Acosta, Manuel, Vera, Isabel, Lorente, Rufo, Vega, Pablo, Diz-Lois, Mar��a Teresa, Fuentes Coronel, Ana Mar��a, P��rez Calle, Jos�� L��zaro, Casis, Bego��a, Ferreiro-Iglesias, Roc��o, Calvo, Marta, Olivares, David, and Alba, Cristina

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tag-10.1177_17562848211056157 for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study by Carlos Taxonera, Mar��a Pilar Mart��nez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, Mar��a Teresa Diz-Lois, Ana Mar��a Fuentes Coronel, Jos�� L��zaro P��rez Calle, Bego��a Casis, Roc��o Ferreiro-Iglesias, Marta Calvo, David Olivares and Cristina Alba in Therapeutic Advances in Gastroenterology

Published
2021
Full Text
View/download PDF

49. sj-docx-2-tag-10.1177_17562848211056157 ��� Supplemental material for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

Author

Taxonera, Carlos, Mart��nez-Montiel, Mar��a Pilar, Barreiro-de-Acosta, Manuel, Vera, Isabel, Lorente, Rufo, Vega, Pablo, Diz-Lois, Mar��a Teresa, Fuentes Coronel, Ana Mar��a, P��rez Calle, Jos�� L��zaro, Casis, Bego��a, Ferreiro-Iglesias, Roc��o, Calvo, Marta, Olivares, David, and Alba, Cristina

Subjects
FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tag-10.1177_17562848211056157 for Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study by Carlos Taxonera, Mar��a Pilar Mart��nez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, Mar��a Teresa Diz-Lois, Ana Mar��a Fuentes Coronel, Jos�� L��zaro P��rez Calle, Bego��a Casis, Roc��o Ferreiro-Iglesias, Marta Calvo, David Olivares and Cristina Alba in Therapeutic Advances in Gastroenterology

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results